• MGB Biopharma

  Participated · Equity · Sep 2014

  MGB Biopharma is a clinical-stage company developing a novel class of anti-infectives, headquartered in Glasgow, Scotland. Its lead candidate, MGB-BP-3, is being developed as an oral formulation for the treatment of Clostridium difficile-associated diarrhoea (CDAD). The company also maintains a pipeline of early preclinical compounds targeting Gram-positive, Gram-negative and antifungal pathogens. MGB Biopharma acquired rights to the proprietary minor groove binder (MGB) platform from the University of Strathclyde with exclusive worldwide licensing rights for all anti-infective fields, including Gram-negative bacteria. The company was founded in 2010 and recently completed a funding round of undisclosed amount. It plans to use the funds to complete activities around its ongoing Phase IIa trial of MGB-BP-3, prepare for subsequent development stages, and progress other programmes through to H2 2020. MGB Biopharma develops MGB-BP-3, an antibacterial active against a broad range of multi-resistant and susceptible Gram-positive pathogens. The company has an oral formulation of MGB-BP-3 for treatment of Clostridium difficile-associated disease (CDAD) and completed a Phase I study. It is preparing a Phase II study designed to investigate safety and efficacy in patients with CDAD, including the virulent ribotype B1/NAP1/027. An intravenous formulation targeting systemic hospital-acquired Gram-positive infections is in late-stage preclinical development. A topical formulation for serious skin infections has shown encouraging efficacy data. The company will use the recently raised funds to advance MGB-BP-3 toward Phase II. MGB Biopharma is developing a truly novel class of anti-infectives based on minor groove binder (MGB) technology; its lead candidate MGB-BP-3 targets a broad range of multi-resistant Gram-positive pathogens including Clostridium difficile and Staphylococcus species. The company has an oral formulation ready to enter the clinic for C. difficile and an intravenous formulation in late-stage preclinical development for systemic hospital-acquired Gram-positive infections. An oral Phase I trial is planned as a single-centre, double-blind, placebo-controlled study enrolling ~40 healthy subjects to assess safety, tolerability and effects on gut flora, expected to start in the first half of 2015. The IV formulation is being advanced in parallel and the company expects to be IND-ready by the end of next year. MGB Biopharma holds an exclusive worldwide licence to the University of Strathclyde's MGB patents (excluding anticancer) and intends to work with partners to capitalise on its platform. The company was founded in 2010 and is headquartered in Glasgow, Scotland. It has secured funding this year to advance clinical development.

• Inquisitive Systems

  Participated · Equity · Apr 2013

  Inquisitive Systems is an Edinburgh-based provider of data protection software focused on intellectual property protection. Its core product, ZoneFox, examines relevant data, provides immediate alerts, and offers full forensic user activity monitoring. The software is intended to protect reputation as well as critical business data from security breaches. The company raised £500k in funding to support development and customer adoption. It intends to use the capital to add resources to its development team and increase adoption of ZoneFox among customers. The company is led by founder and CEO Jamie Graves.

• Design LED Products

  Participated · Equity · Aug 2011

  Design LED Products, formed in 2004 and based in Livingston, UK, develops and patents technology to embed light-emitting diodes (LEDs) within printed light-guide devices. Its core product enables clients to produce thin, flexible, high-efficiency light panels and displays suitable for consumer electronic devices through to large-area LED lighting and LCD TV backlighting. The company is led by CEO Stuart Bain. It intends to use the newly raised funds to accelerate plans to enter the high-growth lighting and LCD TV backlighting markets. The article reports a second tranche close of £639k as part of an ongoing funding round. Prior investor participation and the staged closes indicate continued external investor support as the company pursues market entry.

• Biopta

  Participated · Equity · Nov 2010

  Biopta develops human tissue testing techniques to conduct non-clinical trials on new drugs using donated, residual human tissue collected from surgery. The company was spun out from Glasgow Caledonian University in 2002 and is based in Glasgow, UK. It will use the new funds to expand research and development of its human tissue testing methods. Biopta secured £265,000 in a second round of funding from existing and institutional backers. Investors in this round include Braveheart Investment Group, TRI Cap, the Scottish Co-Investment Fund and the company’s board of directors. The company had previously raised £900,000 in December 2008 from the same group of investors.

No current team members are available.